Effects of farnesyl pyrophosphate accumulation on calvarial osteoblast differentiation

Endocrinology

Volumn 152, Issue 8, 2011, Pages 3113-3122

  Weivoda, Megan M ^a   Hohl, Raymond J ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEIN 2; COLLAGEN TYPE 1; COLLAGEN TYPE 1A1; FARNESYL DIPHOSPHATE; GERANYLGERANYL PYROPHOSPHATE; GERANYLTRANSFERASE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; ISOPRENOID; MEVINOLIN; OSTEOCALCIN; SQUALENE SYNTHASE; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG; ZARAGOZIC ACID A;

ANIMAL CELL; ARTICLE; BIOSYNTHESIS; BONE MINERALIZATION; CALVARIA; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL VIABILITY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SPECIFICITY; ENZYME SUBSTRATE; GENE EXPRESSION; GENE SEQUENCE; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION;

ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; FARNESYLTRANSTRANSFERASE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; OSTEOBLASTS; POLYISOPRENYL PHOSPHATES; RATS; RATS, SPRAGUE-DAWLEY; SESQUITERPENES; TERPENES; TRICARBOXYLIC ACIDS;

EID: 79960738080     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2011-0016     Document Type: Article

References (54)

1. Compston J 2010 Osteoporosis: social and economic impact. Radiol Clin N Am 48:477-482
2. Kanis J 1994 Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO study group. Osteoporosis Int 4:368-381
3. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A 2007 Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 22:465-475 (Pubitemid 46797130)
4. Canalis E 2010 Update in new anabolic therapies for osteoporosis. J Clin Endocrinol Metab 95:1496-1504
5. Girotra M, Rubin MR, Bilezikian JP 2006 Anabolic skeletal therapy for osteoporosis. Arq Bras Endocrinol Metab 50:745-754 (Pubitemid 44786010)
6. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G 1999 Stimulation of bone formation in vitro and in rodents by statins. Science 286:1946-1949 (Pubitemid 129515901)
7. Ruiz-Gaspa S, Nogues X, Enjuanes A, Monllau JC, Blanch J, Carreras R, Mellibovsky L, Grinberg D, Balcells S, Díez-Perez A, Pedro-Botet J 2007 Simvastatin and atorvastatin enhance gene expression of collagen type 1 and osteocalcin in primary human osteoblasts and MG-63 cultures. J Cell Biochem 101:1430-1438 (Pubitemid 47242774)
8. Chen PY, Sun JS, Tsuang YH, Chen MH, Weng PW, Lin FH 2010 Simvastatin promotes osteoblast viability and differentiation via Ras/Smad/Erk/BMP-2 signaling pathway. Nutr Res 30:191-199
9. Maeda T, Matsunuma A, Kawane T, Horiuchi N 2001 Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells. Biochem Bioph Res Co 280:874-877 (Pubitemid 32924513)
10. Maeda T, Kawane T, Horiuchi N 2003 Statins augment vascular endothelial growth factor expression in osteoblastic cells via inhibition of protein prenylation. Endocrinology 144:681-692 (Pubitemid 36205242)
11. Maeda T, Matsunuma A, Kurahashi I, Yanagawa T, Yoshida H, Horiuchi N 2004 Induction of osteoblast differentiation indices by statins in MC3T3-E1 cells. J Cell Biochem 92:458-471
12. Li X, Cui Q, Kao C, Wang GJ, Balian G 2003 Lovastatin inhibits adipogenic and stimulates osteogenic differentiation by suppressing PPARγ2 and increasing Cbfa1/Runx2 expression in bone marrow mesenchymal cell cultures. Bone 33:652-659 (Pubitemid 37222392)
13. Ohnaka K, Shimoda S, Nawata H, Shimokawa H, Kaibuchi K, Iwamoto Y, Takayanagi R 2001 Pitavastatin enhanced BMP-2 and osteocalcin expression by inhibition of Rho-associated kinase in human osteoblasts. Biochem Biophys Res Comm 287:337-342 (Pubitemid 32917601)
14. Pagkalos J, Cha JM, Kang Y, Heliotis M, Tsiridis E, Mantalaris A 2010 Simvastatin induces osteogenic differentiation of murine embryonic stem cells. J Bone Miner Res 25:2470-2478
15. Gutierrez GE, Edwards JR, Garrett IR, Nyman JS, McCluskey B, Rossini G, Flores A, Neidre DB, Mundy GR 2008 Transdermal lovastatin enhances fracture repair in rats. J Bone Miner Res 23:1722-1730
16. Skoglund B, Forslund C, Aspenberg P 2002 Simvastatin improves fracture healing in mice. J Bone Miner Res 17:2004-2008 (Pubitemid 35239202)
17. Chuengsamarn S, Rattanamongkoulgul S, Suwanwalaikorn S, Wattanasirichaigoon S, Kaufman L 2010 Effects of statins vs. non-statin lipid-lowering therapy on bone formation and bone mineral density biomarkers in patients with hyperlipidemia. Bone 46:1011-1015
18. Tang QO, Tran GT, Gamie Z, Graham S, Tsialogiannis E, Tsiridis E, Linder T, Tsiridis E 2008 Statins: under investigation for increasing bone mineral density and augmenting fracture healing. Expert Opin Investig Drugs 17:1435-1463
19. Wang PS, Solomon DH, Mogun H, Avorn J 2000 HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 283:3211-3216 (Pubitemid 30422038)
20. Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret GY 2007 Effects of statins on bone mineral density: a meta-analysis of clinical studies. Bone 40:1581-1587 (Pubitemid 46779004)
21. Endo A 1992 The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 33:1569-1582
22. Endo A, Tsujita Y, Kuroda M, Tanzawa K 1977 Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Eur J Biochem 77:31-36 (Pubitemid 8122952)
23. Siperstein MD, Fagan VM 1966 Feedback control of mevalonate synthesis by dietary cholesterol. J Biol Chem 241:602-609
24. Zhang FL, Casey PJ 1996 Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 65:241-269 (Pubitemid 26250610)
25. Holstein SA, Hohl RJ 2004 Isoprenoids: remarkable diversity of form and function. Lipids 39:293-309 (Pubitemid 38971743)
26. Casey PJ, Seabra MC 1996 Protein prenyltransferases. J Biol Chem 271:5289-5292 (Pubitemid 26083855)
27. Weivoda MM, Hohl RJ 2011 The effects of direct inhibition of geranylgeranyl pyrophosphate synthase on osteoblast differentiation. J Cell Biochem 112:1506-1513
28. Gregory CA, Gunn WG, Peister A, Prockop DJ 2004 An alizarin red-based assay of mineralization by adherent cells in culture: comparison with cetylpyridinium chloride extraction. Anal Biochem 329:77-84 (Pubitemid 38596903)
29. Tong H, Holstein SA, Hohl RJ 2005 Simultaneous determination of farnesyl and geranylgeranyl pyrophosphate levels in cultured cells. Anal Biochem 336:51-59 (Pubitemid 39593499)
30. Shull LW, Wiemer AJ, Hohl RJ, Wiemer DF 2006 Synthesis and biological activity of isoprenoid bisphosphonates. Bioorg Med Chem 14:4130-4136
31. Wiemer AJ, Tong H, Swanson KM, Hohl RJ 2007 Digeranyl bisphosphonate inhibits geranylgeranyl pyrophosphate synthase. Biochem Biophys Res Comm 353:921-925 (Pubitemid 46080385)
32. Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G 2000 Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys 373:231-241 (Pubitemid 30046509)
33. van Beek E, Pieterman E, Cohen L, Löwik C, Papapoulos S 1999 Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Comm 264:108-111 (Pubitemid 29500472)
34. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ 1998 Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTPbinding proteins, including Ras. J Bone Miner Res 13:581-589 (Pubitemid 28163009)
35. Reinholz GG, Getz B, Pederson L, Sanders ES, Subramaniam M, Ingle JN, Spelsberg TC 2000 Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res 60:6001-6007
36. Im GI, Qureshi SA, Kenney J, Rubash HE, Shanbhag AS 2004 Osteoblast proliferation and maturation by bisphosphonates. Biomaterials 25:4105-4115 (Pubitemid 38388576)
37. Kim HK, Kim JH, Abbas AA, Yoon TR 2009 Alendronate enhances osteogenic differentiation of bone marrow stromal cells: a preliminary study. Clin Orthop Relat Res 467:3121-3128
38. Panzavolta S, Torricelli P, Bracci B, Fini M, Bigi A 2009 Alendronate and pamidronate calcium phosphate bone cements: setting properties and in vitro response of osteoblast and osteoclast cells. J Inorg Biochem 103:101-106
39. Duque G, Rivas D 2007 Alendronate has an anabolic effect on bone through the differentiation of mesenchymal stem cells. J Bone Miner Res 22:1603-1611 (Pubitemid 351229330)
40. Fu L, Tang T, Miao Y, Zhang S, Qu Z, Dai K 2008 Stimulation of osteogenic differentiation and inhibition of adipogenic differentiation in bone marrow stromal cells by alendronate via ERK and JNK activation. Bone 43:40-47
41. Ebert R, Zeck S, Krug R, Meissner-Weigl J, Schneider D, Seefried L, Eulert J, Jakob F 2009 Pulse treatment with zoledronic acid causes sustained commitment of bone marrow derived mesenchymal stem cells for osteogenic differentiation. Bone 44:858-864
42. Pozzi S, Vallet S, Mukherjee S, Cirstea D, Vaghela N, Santo L, Rosen E, Ikeda H, Okawa Y, Kiziltepe T, Schoonmaker J, Xie W, Hideshima T, Weller E, Bouxsein ML, Munshi NC, Anderson KC, Raje N 2009 High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties. Clin Cancer Res 15:5829-5839
43. Orriss IR, Key ML, Colston KW, Arnett TR 2009 Inhibition of osteoblast function in vitro by aminobisphosphonates. J Cell Biochem 106:109-118
44. Kellinsalmi M, Monkkonen H, Monkkonen J, Leskela HV, Parikka V, Hamalainen M, Lehenkari P 2005 In vitro comparison of clodronate, pamidronate and zoledronic acid effects on rat osteoclasts and human stem cell-derived osteoblasts. Basic Clin Pharmacol 97:382-391
45. Idris AI, Rojas J, Greig IR, Van't Hof RJ, Ralston SH 2008 Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro. Calcif Tissue Int 82:191-201
46. Yoshida T, Asanuma M, Grossmann L, Fuse M, Shibata T, Yonekawa T, Tanaka T, Ueno K, Yasuda T, Saito Y, Tatsuno I 2006 Geranylgeranyl-pyrophosphate (GGPP) synthase is down-regulated during differentiation of osteoblastic cell line MC3T3-E1. FEBS Lett 580:5203-5207 (Pubitemid 44415791)
47. Takase H, Yano S, Yamaguchi T, Kanazawa I, Hayashi K, Yamamoto M, Yamauchi M, Sugimoto T 2009 Parathyroid hormone upregulates BMP-2 mRNA expression through mevalonate kinase and Rho kinase inhibition in osteoblastic MC3T3-E1 cells. Horm Metab Res 41:861-865
48. Das S, Schapira M, Tomic-Canic M, Goyanka R, Cardozo T, Samuels HH 2007 Farnesyl pyrophosphate is a novel transcriptional activator for a subset of nuclear hormone receptors. Mol Endocrinol 21:2672-2686 (Pubitemid 350035150)
49. Forman BM, Goode E, Chen J, Oro AE, Bradley DJ, Perlmann T, Noonan DJ, Burka LT, McMorris T, Lamph WW, Evans RM, Weinberger C 1995 Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 81:687-693
50. Forman BM, Ruan B, Chen J, Schroepfer Jr GJ, Evans RM 1997 The orphan nuclear receptor LXRα is positively and negatively regulated by distinct products of mevalonate metabolism. Proc Natl Acad Sci USA 94:10588-10593
51. Vukelic S, Stojadinovic O, Pastar I, Vouthounis C, Krzyzanowska A, Das S, Samuels HH, Tomic-Canic M 2010 Farnesyl pyrophosphate inhibits epithelialization and wound healing through the glucocorticoid receptor. J Biol Chem 285:1980-1988
52. Bang S, Yoo S, Yang TJ, Cho H, Hwang SW 2010 Farnesyl pyrophosphate is a novel pain-producing molecule via specific activation of TRPV3. J Biol Chem 285:19352-19371
53. Oh DY, Yoon JM, Moon MJ, Hwang JI, Choe H, Lee JY, Kim JI, Kim S, Rhim H, O'Dell DK, Walker JM, Na HS, Lee MG, Kwon HB, Kim K, Seong JY 2008 Identification of farnesyl pyrophosphate and N-arachidonylglycine as endogenous ligands for GPR92. J Biol Chem 283:21054-21064
54. Liliom K, Tsukahara T, Tsukahara R, Zelman-Femiak M, Swiezewska E, Tigyi G 2006 Farnesyl phosphates are endogenous ligands of lysophosphatidic acid receptors: inhibition of LPA GPCR and activation of PPARs. Biochim Biophys Acta 1761:1506-1514 (Pubitemid 44821912)